Clinical application value of bone turnover markers in non-small-cell lung cancer patients with bone metastases

Chinese-German Journal of Clinical Oncology

Volumn 10, Issue 2, 2011, Pages 81-84

  Wang, Zhiyu ^a   Yang, Chen ^a   Yang, Yumei ^a   Shen, Zan ^a   Zhao, Hui ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Bone metastasis; Bone turnover markers; Non small cell lung cancer

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE TURNOVER; CANCER DIAGNOSIS; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PATHOLOGIC FRACTURE; PROGNOSIS; QUANTITATIVE ANALYSIS; RISK ASSESSMENT;

EID: 79955990653     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-011-0729-3     Document Type: Article

References (13)

1. Rodoman GD. Mechnaisms of bone metastasis. N Engl J Med, 2004, 350: 1655-1664.
2. Ebert W, Muley T. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res, 2004, 24: 3193-3201. (Pubitemid 39390972)
3. Alatas F, Alatas O, Metintas M. Usefulness of bone markers for detection of bone metastases in lung cancer patients. Clin Biochem, 2002, 35: 293-296. (Pubitemid 34804899)
4. Koizumi M, Takahashi S, Ogata E. Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer. Breast Cancer, 2003, 10: 21-27.
5. Berruti A, Dogliotti L, Gorzegno G, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem, 1999, 45: 1240-1247. (Pubitemid 29424263)
6. Terpos E, Kiagia M, Karapanagiotou EM, et al. The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res, 2009, 29: 1651-1658.
7. Shimozuma K, Sonoo H, Fukunaga M, et al. Biochemical markers of bone turnover in breast cancer patents with bone metastases: A preliminary report. Jpn J Clin Oncol, 1999, 29: 16-22.
8. Yu J, Di LJ, Wan FL, et al. The clinical significance of bone metabolism biochemical markers in diagnosis of bone metastasis. Chin J Clin Oncol (Chinese), 2005, 32: 1193-1196.
9. Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol, 1991, 68: 74-80.
10. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res, 2005, 15: 57-62. (Pubitemid 41653967)
11. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA, 2003, 100: 10954-10959. (Pubitemid 37140134)
12. Allen JD, van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther, 2002, 1: 417-425.
13. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst, 2005, 97: 59-69.